SHERLOCK 3CG vs. Fluoroscopy in Implantation of PICC-Line

NCT ID: NCT02929368

Last Updated: 2020-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peripherally inserted central catheters, or PICC lines, has now been successfully in use for many years, especially in the chemotherapeutic treatment of oncologic patients or in parenertal nutrition. The implantation of PICC lines is mostly performed under x-ray (fluoroscopy). The aim of the clinical study is to assess the safety and the efficacy of the SHERLOCK-Systems eliminating the confirmatory chest x-ray exposure. Additionally, the SHERLOCK-System immediately confirms the PICC tip position even at the bedside of the patient, thus, saving costs and time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Peripherally inserted central catheters, or PICC lines, are clinically used for many years in the treatment of patients, whereby the implantation occurs under x-ray/fluoroscopy. Female and male patients of legal age that have the medical indication for Power-PICC-Line catheter implantation can be screened for the study. These medical indications include the necessity of chemotherapy in the course of an oncological treatment or parenteral nutrition. The study objective is to test the efficacy and safety of the SHERLOCK system, evaluated by a monocentric, randomized-controlled study. The advantage for the participating patients lies in a reduced radiation exposure due to the discontinued final chest x-ray examination (fluoroscopy). Furthermore, the SHERLOCK system can be deployed directly on ward, at the patient's bedside leading to a cost and time saving. Recruited in- and outpatients (of legal age) with indication for Power-PICC-Line catheter implantation will be randomly assigned to one of the two arms (fluoroscopy or SHERLOCK). Depending on randomization, the Power-PICC implantation occurs either under fluoroscopy or with the SHERLOCK system. All related substances, measures or procedures are performed according to the clinical routine. The medical device is a fully integrated magnetic tracking and ECG-based peripherally inserted central catheter (PICC) tip confirmation technology applied on patients with normal sinus rhythm and placed through a peripheral vein. The Sherlock system is CE-certified since December 2011.

The referral of patients with indication to PICC-Line implantation at the institute of diagnostic and interventional radiology occurs through different departments of the University Hospital Jena. The patients are registered for radiological treatment and checked again by a radiologist if a PICC-Line implantation is indicated. If this is the case, the radiologist conducts an informed consent discussion with the patient about possible complications and risks during intervention and informs him also about a possible study. After signature of the written informed consent, the patient is included. On the intervention day, the patient is randomly assigned to one of the two study arms through RandomTool (Sherlock vs. fluoroscopy). According to randomization group, the PICC catheter is implanted (duration: 30 minutes) and eventually a chest x-ray (fluoroscopy) is performed to assess safety and efficacy.The intervention time from puncture to catheter placement is documented. After intervention, the patient is transferred back to the ward or sent home in hemodynamically stable conditions. The examination of the puncture site before discharge is performed by a ward physician or by the family doctor. 24 h after PICC-Line implantation, the treating physician is contacted and questioned about possible complications (catheter occlusion, haematoma, infection of the puncture site, arm vein thrombosis, pain, etc.), that are then thoroughly documented.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With PICC-Line

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluoroscopy

PICC Implantation under x-ray

Group Type ACTIVE_COMPARATOR

PICC implantation under fluoroscopy

Intervention Type DEVICE

PICC Catheter implantation

Sherlock System (BARD)

PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System

Group Type ACTIVE_COMPARATOR

PICC Implantation under Sherlock System

Intervention Type DEVICE

PICC Catheter implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PICC implantation under fluoroscopy

PICC Catheter implantation

Intervention Type DEVICE

PICC Implantation under Sherlock System

PICC Catheter implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female, male
* adults ≥ 18 years
* medical indication for Power-PICC-Line catheter implantation because of chemotherapy or parenertal nutrition
* in- and outpatients

Exclusion Criteria

* children and adolescents \< 18 years
* systemic or local infection of the interventional location
* known allergy to used material
* general contraindication of Power-PICC-Line catheter implantation
* nonexistent sinus rhythm (5)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jena University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ulf Teichgräber

Director of Radiology Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heike Habrecht, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Jena, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Jena

Jena, Thuringia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Mack V, Nissler D, Kasikci D, Malouhi A, Aschenbach R, Teichgraber U. Magnetic Tracking and Electrocardiography-Guided Tip Confirmation System Versus Fluoroscopy for Placement of Peripherally Inserted Central Catheters: A Randomized, Noninferiority Comparison. Cardiovasc Intervent Radiol. 2020 Dec;43(12):1891-1897. doi: 10.1007/s00270-020-02551-0. Epub 2020 Jun 17.

Reference Type DERIVED
PMID: 32556606 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4567/10/15

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Central Line Study
NCT05534971 RECRUITING PHASE4